XCancer

Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer

Description:

The purpose of this study is to determine whether our drug, 124I-huA33, can safely detect colorectal cancer.

Sponsor:

Memorial Sloan Kettering Cancer Center

Phase:

N/A

Contacts:

Neeta Pandit-Taskar, MD (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT00199862 - Click here to see study on

ClinicalTrials.gov

huA33

Isotope(s):
Target(s):
  • GPA33
Ligand Class: Antibodies
Inclusion
  • Patients must be candidates for clinically indicated surgery/biopsy for primary/metastatic colorectal cancer
  • Primary or metastatic colorectal carcinoma, histologically confirmed at Memorial Sloan-Kettering Cancer Center (MSKCC).
Exclusion
  • Active CNS tumor involvement. Previous treatment with A33 or its fragment and/or a positive test for huA33 HAHA.